Dianthus Therapeutics (DNTH) Institutional Ownership

$28.96

+1.15 (+4.14%)

(As of 09/13/2024 ET)

Current Institutional Ownership Percentage: 47.53%
Number of Institutional Buyers (last 12 months): 25
Total Institutional Inflows (last 12 months): $246.18M

Number of Institutional Sellers (last 12 months): 8
Total Institutional Outflows (last 12 months): $9.29M

Get DNTH Insider Trade Alerts

Want to know when executives and insiders are buying or selling Dianthus Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

DNTH Institutional Buying and Selling by Quarter

Ad Porter & Company

My grim warning about AI stocks

Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.

So go here now to read my new report The Big AI Die-Up… while you still can.

Dianthus Therapeutics Major Shareholders & Ownership History

Export to Excel

Reporting Date	Major Shareholder Name	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/19/2024	Point72 Asset Management L.P.	174,200	$4.51M	0.0%	-50.5%	0.594%
8/15/2024	The Manufacturers Life Insurance Company	9,102	$236K	0.0%	N/A	0.031%
8/15/2024	Point72 Asia Singapore Pte. Ltd.	39,504	$1.02M	0.2%	+281.9%	0.135%
8/14/2024	Fred Alger Management LLC	6,317	$163K	0.0%	-82.6%	0.022%
8/14/2024	Cubist Systematic Strategies LLC	20,976	$543K	0.0%	-13.1%	0.071%
8/14/2024	Point72 DIFC Ltd	12,900	$334K	0.0%	N/A	0.044%
Get the Latest News and Ratings for DNTH and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Dianthus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
8/14/2024	Great Point Partners LLC	757,929	$19.62M	3.8%	+21.3%	2.582%
8/14/2024	Marshall Wace LLP	108,199	$2.80M	0.0%	-4.2%	0.369%
8/9/2024	Renaissance Technologies LLC	88,604	$2.29M	0.0%	-16.2%	0.302%
8/9/2024	Dimensional Fund Advisors LP	19,726	$510K	0.0%	-9.2%	0.067%
8/9/2024	Atlas Venture Life Science Advisors LLC	136,979	$3.55M	0.4%	-26.7%	0.467%
8/9/2024	WINTON GROUP Ltd	10,238	$265K	0.0%	N/A	0.035%
8/8/2024	American Century Companies Inc.	30,432	$788K	0.0%	+38.6%	0.104%
8/1/2024	Rhumbline Advisers	32,138	$832K	0.0%	N/A	0.109%
7/26/2024	Bank of New York Mellon Corp	80,935	$2.10M	0.0%	+860.5%	0.276%
7/12/2024	SG Americas Securities LLC	4,333	$112K	0.0%	N/A	0.015%
5/20/2024	Virtu Financial LLC	12,995	$390K	0.0%	N/A	0.044%
5/17/2024	RA Capital Management L.P.	2,333,000	$69.99M	0.9%	N/A	7.949%
5/16/2024	Janus Henderson Group PLC	375,044	$11.25M	0.0%	N/A	1.278%
5/16/2024	Bain Capital Life Sciences Investors LLC	2,992,028	$89.76M	7.2%	N/A	10.194%
5/14/2024	StemPoint Capital LP	43,456	$1.30M	0.3%	N/A	0.148%
5/10/2024	Acadian Asset Management LLC	4,012	$120K	0.0%	-77.6%	0.014%
5/10/2024	Vanguard Group Inc.	537,828	$16.14M	0.0%	+250.0%	1.833%
5/6/2024	Atlas Venture Life Science Advisors LLC	186,979	$5.61M	0.5%	-21.1%	0.637%
5/2/2024	Hussman Strategic Advisors Inc.	21,000	$630K	0.1%	N/A	0.072%
2/15/2024	Octagon Capital Advisors LP	554,000	$5.76M	0.9%	+15.4%	3.738%
2/14/2024	Vestal Point Capital LP	135,000	$1.40M	0.1%	N/A	0.911%
2/13/2024	Tower Research Capital LLC TRC	2,430	$25K	0.0%	N/A	0.016%
12/6/2023	Citigroup Inc.	3,868	$53K	0.0%	N/A	0.026%
11/15/2023	Laurion Capital Management LP	36,393	$497K	0.0%	N/A	0.960%
11/14/2023	Avidity Partners Management LP	1,217,554	$16.64M	0.7%	N/A	32.125%
11/13/2023	Atlas Venture Life Science Advisors LLC	236,979	$3.24M	0.5%	N/A	6.249%
11/13/2023	Acadian Asset Management LLC	22,299	$303K	0.0%	N/A	0.588%
11/13/2023	FMR LLC	2,218,212	$28.96M	0.0%	N/A	58.497%

(Data available from 1/1/2016 forward)

DNTH Institutional Ownership - Frequently Asked Questions

Who are the largest shareholders of DNTH shares?: During the previous two years, 31 institutional investors and hedge funds held shares of Dianthus Therapeutics. The most heavily invested institutionals were Bain Capital Life Sciences Investors LLC ($89.76M), RA Capital Management L.P. ($69.99M), FMR LLC ($28.96M), Great Point Partners LLC ($19.62M), Avidity Partners Management LP ($16.64M), Vanguard Group Inc. ($16.14M), and Janus Henderson Group PLC ($11.25M).Learn more on DNTH's institutional investors.
What percentage of Dianthus Therapeutics stock is owned by institutional investors?: 47.53% of Dianthus Therapeutics stock is owned by institutional investors. Learn more on DNTH's institutional investor holdings.
Which institutional investors have been buying Dianthus Therapeutics stock?: Of the 25 institutional investors that purchased Dianthus Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Bain Capital Life Sciences Investors LLC ($2.99M), RA Capital Management L.P. ($2.33M), FMR LLC ($2.22M), Avidity Partners Management LP ($1.22M), Vanguard Group Inc. ($384.18K), Janus Henderson Group PLC ($375.04K), and Atlas Venture Life Science Advisors LLC ($236.98K).

How much institutional buying is happening at Dianthus Therapeutics?: Institutional investors have bought a total of 10,420,221 shares in the last 24 months. This purchase volume represents approximately $246.18M in transactions.
Which Dianthus Therapeutics major shareholders have been selling company stock?: The following institutional investors have sold Dianthus Therapeutics stock in the last 24 months: Point72 Asset Management L.P. ($177.90K), Atlas Venture Life Science Advisors LLC ($100K), Fred Alger Management LLC ($30.05K), Renaissance Technologies LLC ($17.10K), Acadian Asset Management LLC ($13.88K), Marshall Wace LLP ($4.73K), and Cubist Systematic Strategies LLC ($3.15K).
How much institutional selling is happening at Dianthus Therapeutics?: Institutional investors have sold a total of 348,808 shares in the last 24 months. This volume of shares sold represents approximately $9.29M in transactions.